Breast Cancer
Conference Coverage
VIDEO: Survival improves when cancer patients self-report symptoms
CHICAGO – With improved survival and a host of other benefits, why wouldn’t you encourage your patients to self-report?
Conference Coverage
VIDEO: Routine genomic testing identifies actionable alterations in 52% of tumors
CHICAGO – A trend was observed in longer overall survival among those patients who received recommended treatments.
Conference Coverage
Immune-agonist combo has activity against several tumor types
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
Conference Coverage
Biomarker predicts prolonged depression in breast cancer patients
SAN FRANCISCO – Elevated cortisol awakening response shows promise.
Conference Coverage
Test goes wide and deep to detect free tumor DNA in blood
CHICAGO – The high-intensity method for detecting circulating free DNA (cfDNA) in plasma found at least one significant genetic variant in samples...
Conference Coverage
VIDEO: Olaparib improves outlook in women with BRCA-related HER2-negative MBC
In phase III results, olaparib reduced the risk of progression or death in women with BRCA-related HER2-negative metastatic breast cancer,...
Conference Coverage
VIDEO: TRK inhibitor shows 76% ORR across diverse cancers harboring TRK fusions
CHICAGO – Lead study investigator David Hyman, MD, discusses the integrated analysis of three larotrectinib trials and the drug’s regulatory...
Conference Coverage
VIDEO: Helping cancer patients cope with psychological side effects
Three studies at the 2017 ASCO annual meeting detail randomized, controlled trials of psychological interventions aimed at helping patients cope...
News
FDA advisory committee supports neratinib approval
Committee members expressed concern about the broadness of the indication proposed by the drug’s maker.
Conference Coverage
Breast cancer liquid biopsies don’t change outcomes....yet
LAS VEGAS – Although circulating tumor cells are prognostic in breast cancer, they aren’t likely to become a part of routine practice until they’...
From the Journals
Five year survival doubles for younger women with de novo MBC
With more women than ever surviving MBC, how will long-term care be affected?